InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – Why Lexaria Bioscience Corp. (NASDAQ: LEXX) Is ‘One to Watch’
July 20, 2021

InvestorNewsBreaks – Why Lexaria Bioscience Corp. (NASDAQ: LEXX) Is ‘One to Watch’

Lexaria Bioscience Corp. (NASDAQ: LEXX) is the global innovator behind the patented DehydraTECH(TM) technology. DehydraTECH increases the effectiveness of lipophilic (fat-soluble) drugs and active ingredients and improves the way active pharmaceutical ingredients enter the bloodstream. It speeds up delivery, increases bioavailability, increases brain absorption, improves drug potency, reduces drug administration cost and masks unwanted taste. A recent article reads, “Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats. The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings.” Led by an experienced management team, Lexaria is focusing its ongoing research and development efforts on developing product candidates across several key billion-dollar segments: oral cannabinoids, antivirals, oral mucosal nicotine, human hormones, ibuprofen and Naproxen, and vitamin D3. The antivirals segment, for example, is “an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.”

To view the full article, visit https://ibn.fm/hxNE1

About Lexaria Bioscience Corp.

Lexaria Bioscience’s proprietary drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats including foods, beverages, oral suspensions, tablets and capsules. DehydraTECH has repeatedly demonstrated, since 2016 with cannabinoids and nicotine, the ability to increase bioabsorption by up to 5 to 10x, reduce onset time of one to two hours to minutes, and mask unwanted tastes; DehydraTECH is also planned to be further evaluated for orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and nicotine. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 19 patents granted and approximately 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioScience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).